Recent News
Read ArticleDr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Guselkumab (Tremfy) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, based on pivotal, Phase 2b/3 QUASAR study showing 50% remission at week 44 (vs 19 PBO) for those on GUS 200 mg q 4 wk https://t.co/YgtujQjNqI https://t.co/9uazZLuoRb
Dr. John Cush @RheumNow ( View Tweet)
JAMA: RCT in 101 chronic low back pain pts showed a single nondeceptive placebo injection reduced LBP intensity for 1 month https://t.co/TmAIHswwli https://t.co/MwdE7MhQKI
Dr. John Cush @RheumNow ( View Tweet)
Moving Forward on RA Prevention Trials
Now that multiple prevention clinical trials for rheumatoid arthritis (RA) have been completed, a group of investigators have reviewed the results and published their recommendations for future trial designs and drug development to assess… https://t.co/ppmWa27tgd https://t.co/lQEtBNRZRm
Dr. John Cush @RheumNow ( View Tweet)
Visit the latest RheumNow Therapeutic Updates to learn more about earlier treatment with biologics to reduce the risk of organ damage in #Lupus #SponsoredbyGSKUSMA https://t.co/ZqWX0rlyfB https://t.co/IsDeUySaZd
Dr. John Cush @RheumNow ( View Tweet)
Different Autoantibody Phenotypes in Juvenile and Adult Myositis
A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.
Read Article
Conservative Treatment of Acute Vertebral Fractures
A network meta-analysis of pain outcomes in patients with acute osteoporotic vertebral compression fractures (VCFs) showed short-term success with calcitonin and NSAIDs in decreasing pain during activity, but long-term… https://t.co/uqQAoypdiV https://t.co/HNgKtzMs03
Dr. John Cush @RheumNow ( View Tweet)
ACR Speaks Against Repeated Cuts to Medicare Reimbursements
The ACR has submitted its comments to the CMS regarding the proposed CY 2025 Medicare Physician Fee Schedule and Quality Payment Program rule and its impact on rheums and rheum interprofessional team members’ ability to… https://t.co/cIjJwOWA5Z https://t.co/sPLZFUxywl
Dr. John Cush @RheumNow ( View Tweet)
Study of 65 myositis pts w/ PM/Scl Abs found ILD as a dominant feature, esp. if double pos. w/ myositis-specific Abs (MSAs 52%). PM/Scl+ more likely women (90 vs 68%), w/ sclerodactyly (16 vs 0%). Double ++ had more ILD (91%) & mortality (21% vs 0) https://t.co/grz7NW410N https://t.co/pdDilBabdf
Links:
Dr. John Cush @RheumNow ( View Tweet)
Increasing Incidence of Morphea
A large EMR derived cohort study of over 10,000 patients with morphea (localized scleroderma) sheds light on its prevalence and associated features.
Read Article
Systematic literature review IVIG in systemic sclerosis included 12 studies, 266 pts. A favorable effect was seen for skin thickening, MSK pain, GI Sxs, Steroid use, QOL. But less effect for pulmonary Dz, PFTs (stabilized?). Studies were not of high-quality… https://t.co/c3Xix9K2XK https://t.co/L3LKwegmkf
Dr. John Cush @RheumNow ( View Tweet)
Guselkumab (Tremfy) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, based on pivotal, Phase 2b/3 QUASAR study showing 50% remission at week 44 (vs 19 PBO) for those on GUS 200 mg q 4 wk https://t.co/kvtqXFUezw https://t.co/NrYi61yerm
Dr. John Cush @RheumNow ( View Tweet)
JAMA: RCT in 101 chronic low back pain pts showed a single nondeceptive placebo injection reduced LBP intensity for 1 month https://t.co/RI9TnvmeMJ https://t.co/BF6UBqMXrD
Dr. John Cush @RheumNow ( View Tweet)
Consensus Guidelines on Pediatric Methotrexate Use
MTX is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects:
-indications and contraindications… https://t.co/6JtIMGOAhq https://t.co/OZJLqAyOnF
Dr. John Cush @RheumNow ( View Tweet)
UK Biobank study of 34209 pts w/ Abdominal MRIs found a dose response assoc. between visceral & subcutaneous fat and chronic MSK pain, moreso in women. Is adiposity causal or casual in the pathogenesis of chronic pain? https://t.co/w4ziJf7FQD https://t.co/SyUfCPOnHX
Dr. John Cush @RheumNow ( View Tweet)
ACR Speaks Against Repeated Cuts to Medicare Reimbursements
ACR
The American College of Rheumatology has submitted its comments to the CMS regarding the proposed CY 2025 Medicare Physician Fee Schedule and Quality Payment Program rule and its impact on rheumatologists and rheumatology interprofessional team members’ ability to provide care to the 53 million Americans living with rheumatic disease.
Read Article
Low Placental Transfer Rates with Risankizumab
There are significant concerns about the safety of drug use during pregnancy and lactation, especially newer biologic agents. This is complicated by a lack of research.
Read Article
Wales registry of primary Unilateral knee replacements (UKRs) for #OA (n 106,206) found no outcome differences based on level of training (15 yr UKR failure rates equal for Trainees/16.4% vs Consultants/17.13% https://t.co/uIo4Sv8Lfu https://t.co/LEMrf3vHaR
Dr. John Cush @RheumNow ( View Tweet)
PsA: Switch or Cycle, the Eternal Question
Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria.
https://t.co/xP65pw5zCw https://t.co/T0nBO3HMIP
Dr. John Cush @RheumNow ( View Tweet)
A low risk of Candida infections with ixekizumab (IXE); integrated analysis of 25; Candida infx rates - PsO:1.9/100 PY (N 6892); PsA 2.0/100 PY (N 1401); axSpA 1.2/100PY (N 932). Most occured only once, were mild/moderate & were oral or genital Candida https://t.co/ZkkPoSzPMW https://t.co/VysnaQ8rpi
Dr. John Cush @RheumNow ( View Tweet)
In elderly onset rheumatoid arthritis, Treg cells are increased, but have decr suppressor activity. Maybe due to elevated Type I IFN with IFN-β suppressing old Tregs and increasing PD-1 expression. https://t.co/51ww481FkJ https://t.co/8EA1fENaFm
Links:
Dr. John Cush @RheumNow ( View Tweet)
From the blog
Podcasts
Systemic Sclerosis Insights (9.13.2024)-
Linger On The Fingers (9.6.2024)
Earlier treatment with biologics to reduce the risk of organ damage-
Running With Data (8.30.2024)
Therapeutic Updates
Earlier treatment with biologics to reduce the risk of organ damage in systemic lupus erythematosus (SLE)
Sponsored by GSK US Medical Affairs
Learn about the importance of reducing organ damage and corticosteroid-associated toxicity in SLE, and how biologics may help to change the course of
the disease by targeting its underlying mechanisms.
Read Post
Are your patients with moderate to severe RA getting the appropriate dose?
Sponsored by Genentech, Inc
Hear experts’ roundtable discussion with Dr. Alvin Wells, Dr. Orrin Troum, Dr. Grace Wright, and Dr. Aaron Broadwell in this video sponsored by Genentech.
Read Post
